Stephen Ma

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers.